Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup
Arcutis Biotherapeutics Inc ARQT
$26.86
▼ -4.04%
($-1.13)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$27.77
Prev Close
$27.99
Day Range
$26.32 – $27.97
52W Range
$13.70 – $31.77
Market Cap
$3.36B
Beta
1.50
EPS (TTM)
$-0.02
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-01-31 |
| Shares Out. | 125,080,000 |
| Website | arcutis.com/ ↗ |
| Phone | 18054185006 |
| Employees | 354 |
| Revenue | $105.4M |
| Gross Profit | $95.6M |
| Net Income | -$11.3M |
| Free Cash Flow | $26.9M |
| Total Assets | $460.0M |
| Total Liabilities | $270.4M |
| Equity | $189.6M |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Arcutis Biotherapeutics Inc is a publicly traded company under the ticker symbol ARQT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)